Keep an eye on the first patient dosed in phase 1 and 2 trials of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD),with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback